The RNA-Seq data show clear evidence of p53-dependent pro-apoptotic gene induction and support a strategy of enhancing CLL cell apoptosis by combining MDM2 inhibitors with BCL-family inhibitors such as venetoclax and navitoclax, as is currently being explored in other leukemia clinical trials [3]. The gene discussed is MDM2; the disease is B-cell chronic lymphocytic leukemia.